Drug screening model meets cancer organoid technology

Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived x...

Full description

Bibliographic Details
Main Authors: Chen Liu, Tianyu Qin, Yuhan Huang, Yuan Li, Gang Chen, Chaoyang Sun
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Translational Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320303326
id doaj-1d8056a249ec4e2a9ab21974254fc772
record_format Article
spelling doaj-1d8056a249ec4e2a9ab21974254fc7722020-11-25T03:54:54ZengElsevierTranslational Oncology1936-52332020-11-011311100840Drug screening model meets cancer organoid technologyChen Liu0Tianyu Qin1Yuhan Huang2Yuan Li3Gang Chen4Chaoyang Sun5Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaCorresponding author.; Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaTumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening.http://www.sciencedirect.com/science/article/pii/S1936523320303326Cancer organoidDrug screeningPrecision therapy
collection DOAJ
language English
format Article
sources DOAJ
author Chen Liu
Tianyu Qin
Yuhan Huang
Yuan Li
Gang Chen
Chaoyang Sun
spellingShingle Chen Liu
Tianyu Qin
Yuhan Huang
Yuan Li
Gang Chen
Chaoyang Sun
Drug screening model meets cancer organoid technology
Translational Oncology
Cancer organoid
Drug screening
Precision therapy
author_facet Chen Liu
Tianyu Qin
Yuhan Huang
Yuan Li
Gang Chen
Chaoyang Sun
author_sort Chen Liu
title Drug screening model meets cancer organoid technology
title_short Drug screening model meets cancer organoid technology
title_full Drug screening model meets cancer organoid technology
title_fullStr Drug screening model meets cancer organoid technology
title_full_unstemmed Drug screening model meets cancer organoid technology
title_sort drug screening model meets cancer organoid technology
publisher Elsevier
series Translational Oncology
issn 1936-5233
publishDate 2020-11-01
description Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening.
topic Cancer organoid
Drug screening
Precision therapy
url http://www.sciencedirect.com/science/article/pii/S1936523320303326
work_keys_str_mv AT chenliu drugscreeningmodelmeetscancerorganoidtechnology
AT tianyuqin drugscreeningmodelmeetscancerorganoidtechnology
AT yuhanhuang drugscreeningmodelmeetscancerorganoidtechnology
AT yuanli drugscreeningmodelmeetscancerorganoidtechnology
AT gangchen drugscreeningmodelmeetscancerorganoidtechnology
AT chaoyangsun drugscreeningmodelmeetscancerorganoidtechnology
_version_ 1724471987333496832